Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLT Applied Therapeutics	$0.48 -3.2%	$0.41	$0.30 ▼ $10.62	$72.01M	1.97	965,951 shs	1.01 million shs
CGTX Cognition Therapeutics	$1.67 +12.1%	$0.64	$0.22 ▼ $1.97	$109.47M	1	8.53 million shs	3.20 million shs
CYAD Celyad	$0.60	$0.67	$0.46 ▼ $3.07	N/A	N/A	N/A	3,009 shs
IRD Opus Genetics	$1.11 -3.5%	$1.07	$0.65 ▼ $1.75	$68.89M	0.01	211,100 shs	108,903 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLT Applied Therapeutics	-3.20%	+10.00%	+4.78%	+28.08%	-91.77%
CGTX Cognition Therapeutics	+12.08%	+51.82%	+155.35%	+424.66%	+120.32%
CYAD Celyad	0.00%	0.00%	0.00%	0.00%	0.00%
IRD Opus Genetics	-3.48%	0.00%	-1.77%	+8.82%	+110,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLT Applied Therapeutics	4.3896 of 5 stars	3.3	3.0	0.0	4.7	2.8	1.7	1.3
CGTX Cognition Therapeutics	3.1339 of 5 stars	3.6	4.0	0.0	0.0	2.5	1.7	0.6
CYAD Celyad	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	1.8216 of 5 stars	3.5	0.0	0.0	0.0	2.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLT Applied Therapeutics	2.50	Moderate Buy	$6.10	1,160.33% Upside
CGTX Cognition Therapeutics	3.25	Buy	$2.83	69.66% Upside
CYAD Celyad	0.00	N/A	N/A	N/A
IRD Opus Genetics	3.00	Buy	$7.33	560.66% Upside

Current Analyst Ratings Breakdown

Latest CYAD, APLT, IRD, and CGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	CGTX Cognition Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/27/2025	IRD Opus Genetics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/26/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
5/27/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLT Applied Therapeutics	$460K	151.52	N/A	N/A	$0.12 per share	4.03
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	$0.10 per share	N/A
CYAD Celyad	$200K	79.56	N/A	N/A	$0.02 per share	30.00
IRD Opus Genetics	$10.99M	6.05	N/A	N/A	$0.29 per share	3.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLT Applied Therapeutics	-$105.62M	-$0.45	N/A	N/A	N/A	N/A	-354.24%	-144.16%	11/6/2025 (Estimated)
CGTX Cognition Therapeutics	-$33.97M	-$0.67	N/A	N/A	N/A	N/A	-251.23%	-130.75%	N/A
CYAD Celyad	-$6.30M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	-$57.53M	-$1.92	N/A	N/A	N/A	-377.89%	-384.33%	-148.90%	N/A

Latest CYAD, APLT, IRD, and CGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	APLT Applied Therapeutics	-$0.17	-$0.15	+$0.02	-$0.15	$0.42 million	N/A
8/13/2025	Q2 2025	IRD Opus Genetics	-$0.25	-$0.12	+$0.13	-$0.12	$4.27 million	$2.88 million
8/7/2025	Q2 2025	CGTX Cognition Therapeutics	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLT Applied Therapeutics	N/A	N/A	N/A	N/A	N/A
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	N/A
CYAD Celyad	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLT Applied Therapeutics	N/A	1.94	1.94
CGTX Cognition Therapeutics	N/A	1.54	1.54
CYAD Celyad	1.49	2.29	2.14
IRD Opus Genetics	0.06	1.90	1.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLT Applied Therapeutics	98.31%
CGTX Cognition Therapeutics	43.35%
CYAD Celyad	N/A
IRD Opus Genetics	14.97%

Insider Ownership

Company	Insider Ownership
APLT Applied Therapeutics	1.60%
CGTX Cognition Therapeutics	14.40%
CYAD Celyad	0.94%
IRD Opus Genetics	6.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLT Applied Therapeutics	30	144.01 million	141.71 million	Optionable
CGTX Cognition Therapeutics	20	73.47 million	62.89 million	Not Optionable
CYAD Celyad	95	26.52 million	26.28 million	Not Optionable
IRD Opus Genetics	14	59.91 million	55.95 million	N/A

CYAD, APLT, IRD, and CGTX Headlines

Recent News About These Companies

Opus Genetics, Inc.: Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

August 18 at 1:06 PM | finanznachrichten.de

Opus Genetics announces FDA clearance of IND application for OPGx-BEST1

August 18 at 1:06 PM | msn.com

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

August 18 at 8:00 AM | globenewswire.com

Opus Genetics, Inc. (NASDAQ:IRD) Just Reported Earnings, And Analysts Cut Their Target Price

August 16, 2025 | finance.yahoo.com

Opus Genetics (NASDAQ:IRD) Issues Earnings Results

August 15, 2025 | marketbeat.com

Opus Genetics, Inc.: Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

August 14, 2025 | finanznachrichten.de

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

August 14, 2025 | finance.yahoo.com

Opus Genetics reports Q2 EPS (12c) vs (30c) last year

August 14, 2025 | msn.com

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

August 13, 2025 | zacks.com

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

August 13, 2025 | globenewswire.com

Opus Genetics (IRD) to Release Earnings on Tuesday

August 10, 2025 | americanbankingnews.com

Opus Genetics (IRD) Expected to Announce Earnings on Tuesday

August 6, 2025 | marketbeat.com

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

August 5, 2025 | globenewswire.com

Opus Genetics & Global RDH12 Alliance partner to advance RDH12 gene therapy for inherited childhood blindness

July 28, 2025 | pharmabiz.comP

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

July 24, 2025 | finance.yahoo.com

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

July 23, 2025 | globenewswire.com

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - Morningstar

July 5, 2025 | morningstar.comM

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 3, 2025 | globenewswire.com

Opus Genetics, Inc. (IRD) Income Statement - Yahoo Finance

June 30, 2025 | finance.yahoo.com

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

June 26, 2025 | globenewswire.com

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

June 23, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYAD, APLT, IRD, and CGTX Company Descriptions

Applied Therapeutics NASDAQ:APLT

$0.48 -0.02 (-3.20%)

Closing price 08/19/2025 04:00 PM Eastern

Extended Trading

$0.50 +0.01 (+2.48%)

As of 08/19/2025 06:47 PM Eastern

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Cognition Therapeutics NASDAQ:CGTX

$1.67 +0.18 (+12.08%)

Closing price 08/19/2025 04:00 PM Eastern

Extended Trading

$1.65 -0.02 (-0.96%)

As of 08/19/2025 07:59 PM Eastern

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Celyad NASDAQ:CYAD

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Opus Genetics NASDAQ:IRD

$1.11 -0.04 (-3.48%)

Closing price 08/19/2025 04:00 PM Eastern

Extended Trading

$1.12 +0.01 (+1.35%)

As of 08/19/2025 07:31 PM Eastern

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time